Company intelligence / Profile preview

Gemphire Therapeutics

Livonia, Michigan, United States

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Gemphire Therapeutics developed gemcabene, a once-daily oral small molecule therapy, and completed three Phase IIb clinical trials in patients with homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, and severe hypertriglyceridemia. The company also targeted NAFLD/NASH but revenue was not reported and the company became inactive following acquisition.

Therapeutic areas: GastroenterologyCardiovascularMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Gemphire Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gemphire Therapeutics.

Explore the full profile